The therapeutic potential of CRF1 antagonists for anxiety

Expert Opinion on Investigational Drugs

Volumn 13, Issue 7, 2004, Pages 799-828

  Zorrilla, Eric P ^a   Koob, George F ^a  

^a The Sripps Research Institute   (United States)

Author keywords

Anxiety; Anxiolytic; Corticotropin releasing factor receptor antagonist; Corticotropin releasing hormone receptor antagonist; Depression; Nonpeptide; Small molecule; Stress

Indexed keywords

1 [8 (2,4 DICHLOROPHENYL) 2 METHYLQUINOLIN 4 YL] 1,2,3,6 TETRAHYDROPYRIDINE 4 CARBOXAMIDE BENZENESULFONATE; 2 [N (2 BROMO 4 ISOPROPYLPHENYL) N ETHYLAMINO] 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 6 METHYLPYRIMIDINE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 3 [(2 BROMO 4 ISOPROPYLPHENYL) 5 METHYL 3H [1,2,3]TRIAZOLO[4,5 D]PYRIMIDIN 7 YL] BIS(2 METHOXYETHYL)AMINE; 3 [6 (DIMETHYLAMINO) 3 PYRIDINYL] 2,5 DIMETHYL N,N DIPROPYLPYRAZOLO[2,3 A]PYRIMIDIN 7 AMINE; 4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; 4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL)THIAZOL 2 AMINE; 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 2 [N ETHYL N (4 ISOPROPYL 2 METHYLTHIOPHENYL)AMINO] 6 METHYLPYRIMIDINE; 4 [5,6 DIHYDRO 3 (2 METHYLPHENYL) 1(2H) PYRIDINYL] N ETHYL 6 METHYL N [4 (1 METHYLETHYL) 2 (METHYLTHIO)PHENYL]; 5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; 8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; ANTALARMIN; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CC 2064460; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CRA 0316; CRA 0450; DMP 695; DMP 904; HYDRAZIDE DERIVATIVE; IMIDAZOLINE DERIVATIVE; N (1 ETHYLPROPYL) 3 (4 METHOXY 2 METHYLPHENYL) 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDIN 7 AMINE; N (2 CHLORO 4,6 DIMETHYLPHENYL) 1 [1 METHOXYMETHYL(2 METHOXYETHYL)] 6 METHYL 1H 1,2,3 TRIAZOLO[4,5 C]PYRIDIN 4 AMINE MESYLATE; N (2 METHYL 4 METHOXYPHENYL) 1 [1 (METHOXYMETHYL)PROPYL] 6 METHYL 1H 1,2,3 TRIAZOLO[4,5 C]PYRIDIN 4 AMINE; N (CYCLOPROPYLMETHYL) N PROPYL 2 [(2,4,6 TRICHLOROPHENYL)AMINO] 4 (TRIFLUOROMETHYL) 5 THIAZOLEMETHANAMINE; PHENAZINE DERIVATIVE; PYRAZOLONE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRIMIDINONE DERIVATIVE; PYRROLOPYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; R 121920; R 278995; SN 003; UNCLASSIFIED DRUG; UNINDEXED DRUG; CRF RECEPTOR TYPE 1;

ANXIETY DISORDER; CEREBROSPINAL FLUID LEVEL; CHEMICAL MODIFICATION; CLINICAL TRIAL; DRUG ABUSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG TARGETING; HEADACHE; HUMAN; HYDROPHILICITY; HYPNOSIS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LEARNING DISORDER; LIPOPHILICITY; MEMORY DISORDER; MENTAL STRESS; NEUROENDOCRINE DISEASE; NONHUMAN; PH; PHARMACOPHORE; PSYCHOSOMATICS; REVIEW; SEDATION; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; ANIMAL; ANXIETY; DRUG ANTAGONISM;

ANIMALS; ANXIETY; HUMANS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE;

EID: 3543078103     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.7.799     Document Type: Review

References (353)

1. KESSLER RC, McGONAGLE KA, ZHAO S et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry. (1994) 51:8-19.
2. DUPONT RL, RICE DP, MILLER LS et al.: Economic costs of anxiety disorders. Anxiety. (1996) 2:167-172.
3. LEPINE JP: The epidemiology of anxiety disorders: prevalence and societal costs. J. Clin. Psychiatry. (2002) 63(Suppl. 14):4-8.
4. KENDLER KS, DAVIS CG, KESSLER RC: The familial aggregation of common psychiatric and substance use disorders in the National Comorbidity Survey: a family history study. Br. J. Psychiatry. (1997) 170:541-548.
5. WITTCHEN HU, ZHAO S, KESSLER RC, EATON WW: DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch. Gen. Psychiatry. (1994) 51:355-364.
6. JUDD LL, KESSLER RC, PAULUS MP et al.: Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS). Acta. Psychiatr. Scand. Suppl. (1998) 393:6-11.
7. GOODWIN RD, STAYNER DA, CHINMAN MJ et al.: The relationship between anxiety and substance use disorders among individuals with severe affective disorders. Compr. Psychiatry (2002) 43:245-252.
8. SEWELL MC, GOGGIN KJ, RABKIN JG et al.: Anxiety syndromes and symptoms among men with AIDS: a longitudinal controlled study. Psychosomatics (2000) 41:294-300.
9. McWILLIAMS LA, COX BJ, ENNS MW: Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Pain (2003) 106:127-133.
10. GOODWIN RD, STEIN MB: Generalized anxiety disorder and peptic ulcer disease among adults in the United States. Psychosom. Med. (2002) 64:862-866.
11. LECRUBIER Y: The burden of depression and anxiety in general medicine. J. Clin. Psychiatry. (2001) 62(Suppl. 8):4-9.
12. STEIN MB: Attending to anxiety disorders in primary care. J. Clin. Psychiatry. (2003) 64(Suppl. 15):35-39.
13. GREENBERG PE, SISITSKY T, KESSLER RC et al.: The economic burden of amxiety disorders in the 1990s. J. Clin. Psychiatry (1999) 60:427-435.
14. RICE DP, MILLER LS: Health economics and cost implications of anxiety and other mental disorders in the United States. Br. J. Psychiatry Suppl. (1998) 34:4-9.
15. WITTCHEN HU: Generalized anxiety disorder: prevalence, burden, and cost to society. Depress. Anxiety. (2002) 16:162-171.
16. KHAN A, LEVENTHAL RM, KHAN S, BROWN WA: Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database. J. Affect. Disord. (2002) 68:183-190.
17. ALLGULANDER C: Suicide and mortality patterns in anxiety neurosis and depressive neurosis. Arch. Gen. Psychiatry. (1994) 51:708-712.
18. ALLGULANDER C, LAVORI PW: Excess mortality among 3302 patients with 'pure' anxiety neurosis. Arch. Gen. Psychiatry. (1991) 48:599-602.
19. MENDLOWICZ MV, STEIN MB: Quality of life in individuals with anxiety disorders. Am. J. Psychiatry. (2000) 157:669-682.
20. YOUNG AS, KLAP R, SHERBOURNE CD, WELLS KB: The quality of care for depressive and anxiety disorders in the United States. Arch. Gen. Psychiatry. (2001) 58:55-61.
21. RODRIGUEZ BF, WEISBERG RB, PAGANO ME et al.: Mental health treatment received by primary care patients with posttraumatic stress disorder. J. Clin. Psychiatry. (2003) 64:1230-1236.
22. BALLENGER JC, DAVIDSON JR, LECRUBIER, Y et al.: Consensus statement on social anxiety disorder from the International Consensus Group on Depression Anxiety. J. Clin. Psychiatry. (1998) 59(Suppl. 17):54-60.
23. BALLENGER JC, DAVIDSON JR, LECRUBIER Y et al.: Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression Anxiety. J. Clin. Psychiatry. (2001) 62(Suppl. 11):53-58.
24. BALLENGER JC, DAVIDSON JR, LECRUBIER Y et al.: Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression Anxiety. J. Clin. Psychiatry. (2000) 61(Suppl. 5):60-66.
25. JENIKE MA: Clinical practice. Obsessive-compulsive disorder. N. Engl. J. Med. (2004) 350:259-265.
26. WOODS JH, KATZ JL, WINGER G: Benzodiazepines: use, abuse, and consequences. Pharmacol. Rev. (1992) 44:151-347.
27. DE SOUZA EB: Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. Psychoneuroendocrinology (1995) 20:789-819.
28. KOOB GF, HEINRICHS SC: A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res. (1999) 848:141-152.
29. VALE W, SPIESS J, RIVIER C, RIVIER J: Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science (1981) 213:1394-1397.
30. VAUGHAN J, DONALDSON C, BITTENCOURT J et al.: Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature (1995) 378:287-292.
31. REYES TM, LEWIS K, PERRIN MH et al.: Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by Type 2 CRF receptors. Proc. Natl. Acad. Sci. USA (2001) 98:2843-2848.
32. LEWIS K, LI C, PERRIN MH et al.: Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. USA (2001) 98:7570-7575.
33. HSU SY, HSUEH AJ: Human stresscopin and stresscopin-related peptide are selective ligands for the Type 2 corticotropin-releasing hormone receptor. Nat Med. (2001) 7:605-611.
34. ZORRILLA EP, TACHÉ Y, KOOB GF: Nibbling at CRF receptor control of feeding and gastrocolonic motility. Trends Pharmacol. Sci. (2003) 24:421-427.
35. PERRIN MH, VALE WW: Corticotropin releasing factor receptors and their ligand family. Ann. NY Acad. Sci. (1999) 885:312-328.
36. OWENS MJ, NEMEROFF CB: Corticotropin-releasing factor antagonists in affective disorders. Expert Opin. Investig. Drugs. (1999) 8:1849-1858.
37. HAUGER RL, GRIGORIADIS DE, DALLMAN MF et al.: International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol. Rev. (2003) 55:21-26.
38. DAUTZENBERG FM, KILPATRICK GJ, HAUGER RL, MOREAU J: Molecular biology of the CRH receptors- in the mood. Peptides. (2001) 22:753-760.
39. HARMAR AJ: Family-B G-protein-coupled receptors. Genome. Biol. (2001) 2(12):REVIEWS3013.
40. DAUTZENBERG FM, PY-LANG G, HIGELIN J et al.: Different binding modes of amphibian and human corticotropin-releasing factor Type 1 and Type 2 receptors: evidence for evolutionary differences. J. Pharmacol. Exp. Ther. (2001) 296:113-120.
41. BEHAN DP, GRIGORIADIS DE, LOVENBERG T et al.: Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders. Mol Psychiatry. (1996) 1:265-277.
42. ORTH DN, MOUNT CD: Specific high-affinity binding protein for human corticotropin-releasing hormone in normal human plasma. Biochem. Biophys. Res. Commun. (1987) 143:411-417.
43. BEHAN DP, LINTON EA, LOWRY PJ: Isolation of the human plasma corticotrophin-releasing factor-binding protein. J. Endocrinol. (1989) 122:23-31.
44. SUTTON SW, BEHAN DP, LAHRICHI SL et al.: Ligand requirements of the human corticotropin-releasing factor-binding protein. Endocrinol. (1995) 136:1097-1102.
45. BAIGENT SM, LOWRY PJ: Urocortin is the principal ligand for the corticotrophin-releasing factor binding protein in the ovine brain with no evidence for a sauvagine-like peptide. J. Mol. Endocrinol. (2000) 24:53-63.
46. BEHAN DP, DE SOUZA EB, LOWRY PJ, et al.: Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides. Front. Neuroendocrinology (1995) 16:362-382.
47. KEMP CF, WOODS RJ, LOWRY PJ: The corticotrophin-releasing factor-binding protein: an act of several parts. Peptides. (1998) 19:1119-1128.
48. CHAN RK, VALE WW, SAWCHENKO PE: Paradoxical activational effects of a corticotropin-releasing factor-binding protein 'ligand inhibitor' in rat brain. Neurosci. (2000) 101:115-129.
49. JAHN O, ECKART K, SYDOW S, HOFMANN BA, SPIESS J: Pharmacological characterization of recombinant rat corticotropin releasing factor binding protein using different sauvagine analogs. Peptides (2001) 22:47-56.
50. WEBSTER EL, LEWIS DB, TORPY DJ et al.: In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinol. (1996) 137:5747-5750.
51. SMITH GW, AUBRY JM, DELLU F et al.: Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron (1998) 20:1093-1102.
52. BRUHN TO, SUTTON SW, PLOTSKY PM, VALE WW: Central administration of corticotropin-releasing factor modulates oxytocin secretion in the rat. Endocrinol. (1986) 119:1558-1563.
53. BROWN MR, RIVIER C, VALE W: Central nervous system regulation of adrenocorticotropin secretion: role of somatostatins. Endocrinol. (1984) 114:1546-1549.
54. VENIHAKI M, MAJZOUB J: Lessons from CRH knockout mice. Neuropeptides (2002) 36:96-102.
55. VETTER DE, LI C, ZHAO L et al.: Urocortin-deficient mice show hearing impairment and increased anxiety-like behavior. Nat. Genet. (2002) 31:363-369.
56. TURNBULL AV, VAUGHAN J, RIVIER JE, VALE WW, RIVIER C: Urocortin is not a significant regulator of intermittent electrofootshock-induced adrenocorticotropin secretion in the intact male rat. Endocrinol. (1999) 140:71-78.
57. HARA Y, UETA Y, ISSE T et al.: Increase of urocortin-like immunoreactivity in the rat supraoptic nucleus after dehydration but not food deprivation. Neurosci. Lett. (1997) 229:65-68.
58. DAUTZENBERG FM, HAUGER RL: The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol. Sci. (2002) 23:71-77.
59. SANCHEZ MM, YOUNG LJ, PLOTSKY PM, INSEL TR: Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J. Comp. Neurol. (1999) 408:365-377.
60. VAN PETT K, VIAU V, BITTENCOURT JC et al.: Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J. Comp. Neurol. (2000) 429:191-212.
61. CHALMERS DT, LOVENBERG TW, GRIGORIADIS DE, BEHAN DP, DE SOUZA EB: Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol. Sci. (1996) 17:166-172.
62. POTTER E, SUTTON S, DONALDSON C et al.: Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc. Natl. Acad. Sci. USA (1994) 91:8777-8781.
63. KOSTICH WA, CHEN A, SPERLE K, LARGENT BL: Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2-γ receptor. Mol. Endocrinol. (1998) 12:1077-1085.
64. CHARLTON BG, FERRIER IN, PERRY RH: Distribution of corticotropin-releasing factor-like immunoreactivity in human brain. Neuropeptides (1987) 10:329-334.
65. CHAPPELL PB, SMITH MA, KILTS CD et al.: Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress. J. Neurosci. (1986) 6:2908-2914.
66. MERCHENTHALER I, VIGH S, PETRUSZ P, SCHALLY AV: Immunocytochemical localization of corticotropin-releasing factor (CRF) in the rat brain. Am J. Anat. (1982) 165:385-396.
67. MERCHENTHALER I: Corticotropin releasing factor (CRF)-like immunoreactivity in the rat central nervous system. Extrahypothalamic distribution. Peptides (1984) 5(Suppl. 1):53-69.
68. SWANSON LW, SAWCHENKO PE, RIVIER J, VALE WW: Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology (1983) 36:165-186.
69. PALKOVITS M, BROWNSTEIN MJ, VALE W: Distribution of corticotropin-releasing factor in rat brain. Fed. Proc. (1985) 44:215-219.
70. ZORRILLA EP, KOOB GF, The roles of urocortins 1, 2 and 3 in the brain. In: Techniques in the Behavioral and Neural Sciences (Volume 14). Handbook of Stress, Immunology and Behaviour. T Steckler, N Kalin, H Reul (Eds) Elsevier Science, New York (2004).
71. SMAGIN GN, HEINRICHS SC, DUNN AJ: The role of CRH in behavioral responses to stress. Peptides. (2001) 22:713-724.
72. DUNN AJ, BERRIDGE CW: Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res. Rev. (1990) 15:71-100.
73. EHLERS CL, HENRIKSEN SJ, WANG M et al.: Corticotropin releasing factor produces increases in brain excitability and convulsive seizures in rats. Brain Res. (1983) 278:332-336.
74. EHLERS CL: EEG stability following corticotropin releasing factor in rats. Psychoneuroendocrinology (1986) 11:121-125.
75. WEISS SR, POST RM, GOLD PW et al.: CRF-induced seizures and behavior: interaction with amygdala kindling. Brain Res. (1986) 372:345-351.
76. MARROSU F, FRATTA W, CARCANGIU P, GIAGHEDDU M, GESSA GL: Localized epileptiform activity induced by murine CRF in rats. Epilepsia (1988) 29:369-373.
77. BARAM TZ, SCHULTZ L: Corticotropin-releasing hormone is a rapid and potent convulsant in the infant rat. Brain Res. Dev. Brain Res. (1991) 61:97-101.
78. SLAWECKI CJ, SOMES C, RIVIER JE, EHLERS CL: Neurophysiological effects of intracerebroventricular administration of urocortin. Peptides (1999) 20:211-218.
79. 1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, nonpeptide CRF receptor antagonist. Brain Res. (1997) 770:89-95.
80. SCHULZ DW, MANSBACH RS, SPROUSE J et al.: CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc. Natl. Acad. Sci. USA (1996) 93:10477-10482.
81. OKUYAMA S, CHAKI S, KAWASHIMA N et al.: Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J. Pharmacol. Exp. Ther. (1999) 289:926-935.
82. SUTTON RE, KOOB GF, LE MOAL M, RIVIER J, VALE W: Corticotropin releasing factor produces behavioural activation in rats. Nature (1982) 297:331-333.
83. KOOB GF, THATCHER-BRITTON K: Stimulant and anxiogenic effects of corticotropin releasing factor. Prog. Clin. Biol. Res. (1985) 192:499-506.
84. SPINA M, MERLO-PICH E, CHAN RK et al.: Appetite-suppressing effects of urocortin, a CRF-related nearopeptide. Science. (1996) 273:1561-1564.
85. KALIN NH, SHELTON SE, KRAEMER GW, McKINNEY WT: Corticotropin-releasing factor administered intraventricularly to rhesus monkeys. Peptides (1983) 4:217-220.
86. WINSLOW JT, NEWMAN JD, INSEL TR: CRH and alpha-helical-CRH modulate behavioral measures of arousal in monkeys. Pharmacol. Biochem. Behav. (1989) 32:919-926.
87. JOHNSON RW, VON BORELL EH, ANDERSON LL, KOJIC LD, CUNNICK JE: Intracerebroventricular injection of corticotropin-releasing hormone in the pig: acute effects on behavior, adrenocorticotropin secretion, and immune suppression. Endocrinol. (1994) 135:642-648.
88. SALAK-JOHNSON JL, McGLONE JJ, WHISNANT CS, NORMAN RL, KRAELING RR: Intracerebroventricular porcine corticotropin-releasing hormone and cortisol effects on pig immune measures and behavior. Physiol. Behav. (1997) 61:15-23.
89. PARROTT RF, VELLUCCI SV: Behaviour of pigs given corticotrophin-releasing hormone in combination with flumazenil or diazepam. Pharmacol. Biochem. Behav. (2000) 67:465-471.
90. PARROTT RF, VELLUCCI SV, GOODE JA: Behavioral and hormonal effects of centrally injected 'anxiogrnic' neuropeptides in growing pigs. Pharmacol. Biochem. Behav. (2000) 65:123-129.
91. OPP M, OBAL F Jr, KRUEGER JM: Corticotropin-releasing factor attenuates interleukin 1-induced sleep and fever in rabbits. Am. J. Physiol. (1989) 257:R528-R535.
92. DUNN AJ, BERRIDGE CW: Corticotropin-releasing factor administration elicits a stress-like activation of cerebral catecholaminergic systems. Pharmacol. Biochem. Behav. (1987) 27:685-691.
93. DUNN AJ, BERRIDGE CW, LAI YI, YACHABACH TL: CRF-induced excessive grooming behavior in fats and mice. Peptides (1987) 8:841-844.
94. ZHANG R, NAKANISHI T, OHGUSHI A et al.: Interaction of corticotropin-releasing factor and glucagon-like peptide-1 on behaviors in chicks. Eur. J. Pharmacol. (2001) 430:73-78.
95. OHGUSHI A, BUNGO T, SHIMOJO M et al.: Relationships between feeding and locomotion behaviors after central administration of CRF in chicks. Physiol. Behav. (2001) 72:287-289.
96. CLEMENTS S, SCHRECK CB, LARSEN DA, DICKHOFF WW: Central administration of corticotropin-releasing hormone stimulates locomotor activity in juvenile chinook salmon (Oncorhynchus tshawytscha). Gen. Comp. Endocrinol. (2002) 125:319-327.
97. LOWRY CA, BURKE KA, RENNER KJ, MOORE FL, ORCHINIK M: Rapid changes in monoamine levels following administration of corticotropin-releasing factor or corticosterone are localized in the dorsomedial hypothalamus. Horm. Behav. (2001) 39:195-205.
98. LOWRY CA, MOORE FL: Corticotropin-releasing factor (CRF) antagonist suppresses stress-induced locomotor activity in an amphibian. Horm. Behav. (1991) 25:84-96.
99. LOWRY CA, DEVICHE P, MOORE FL: Effects of corticotropin-releasing factor (CRF) and opiates on amphibian locomotion. Brain Res. (1990) 513:94-100.
100. VALDEZ GR, INOUE K, KOOB GF et al.: Human urocortin II: Mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide. Brain Res. (2002) 943:142-150.
101. VALDEZ GR, ZORRILLA EP, RIVIER J, VALE WW, KOOB GF: Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective Type 2 corticotropin-releasing factor agonist. Brain Res. (2003) 980:206-212.
102. CONTARINO A, DELLU F, KOOB GF et al.: Dissociation of locomotor activation and suppression of food intake induced by CRF in CRFR1-deficient mice. Endocrinol. (2000) 141:2698-2702.
103. ZORRILLA EP, VALDEZ GR, NOZULAK J, KOOB GF, MARKOU A: Effects of antalarmin, a CRF Type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res. (2002) 952:188-199.
104. MOREAU JL, KILPATRICK G, JENCK F: Urocortin, a novel neuropeptide with anxiogenic-like properties. Neuroreport (1997) 8:1697-1701.
105. JONES DN, KORTEKAAS R, SLADE PD, MIDDLEMISS DN, HAGAN JJ: The behavioural effects of corticotropin-releasing factor-related peptides in rats. Psychopharmacology (1998) 138:124-132.
106. SPINA MG, MERLO-PICH E, AKWA Y et al.: Time-dependent induction of anxiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat. Psychopharmacology (2002) 160:113-121.
107. BALDWIN HA, RASSNICK S, RIVIER J, KOOB GF, BRITTON KT: CRF antagonist reverses the 'anxiogenic' response to ethanol withdrawal in the rat. Psychopharmacology (1991) 103:227-232.
108. MOMOSE K, INUI A, ASAKAWA A et al.: Intracerebroventricularly administered corticotropin-releasing factor inhibits food intake and produces anxiety-like behaviour at very low doses in mice. Diabetes Obes. Metab. (1999) 1:281-284.
109. TAKAHASHI LK, KALIN NH, VANDEN BURGT JA, SHERMAN JE: Corticotropin-releasing factor modulates defensive-withdrawal and exploratory behavior in rats. Behav. Neurosci. (1989) 103:648-654.
110. YANG XM, GORMAN AL, DUNN AJ: The involvement of central noradrenergic systems and corticotropin- releasing factor in defensive-withdrawal behavior in rats. J. Pharmacol. Exp. Ther. (1990) 255:1064-1070.
111. BERRIDGE CW, DUNN AJ: CRF and restraint-stress decrease exploratory behavior in hypophysectomized mice. Pharmacol. Biochem. Behav. (1989) 34:517-519.
112. BRITTON KT, MORGAN J, RIVIER J, VALE W, KOOB GF: Chlordiazepoxide attenuates response suppression induced by corticotropin-releasing factor in the conflict test. Psychopharmacology (1985) 86:170-174.
113. DE BOER SF, KATZ JL, VALENTINO RJ: Common mechanisms underlying the proconflict effects of corticotropin-releasing factor, a benzodiazepine inverse agonist and electric foot-shock. J. Pharmacol. Exp. Ther. (1992) 262:335-342.
114. COLE BJ, KOOB GF: Propranolol antagonizes the enhanced conditioned fear produced by corticotropin releasing factor. J. Pharmacol. Exp. Ther. (1988) 247:902-910.
115. GUPTA P, BRUSH FR: Differential behavioral and endocrinological effects of corticotropin-releasing hormone (CRH) in the Syracuse high- and low-avoidance rats. Horm. Behav. (1998) 34:262-267.
116. HEINRICHS SC, JOPPA M: Dissociation of arousal-like from anxiogenic-like actions of brain corticotropin-releasing factor receptor ligands in rats. Behav. Brain Res.. (2001) 122:43-50.
117. SHERMAN JE, KALIN NH: ICV-CRH alters stress-induced freezing behavior without affecting pain sensitivity. Pharmacol. Biochem. Behav. (1988) 30:801-807.
118. DUNN AJ, FILE SE: Corticotropin-releasing factor has an anxiogenic action in the social interaction test. Horm. Behav. (1987) 21:193-202.
119. MELE A, CABIB S, OLIVERIO A, MELCHIORRI P, PUGLISI-ALLEGRA S: Effects of corticotropin releasing factor and sauvagine on social behavior of isolated mice. Peptides (1987) 8:935-938.
120. ELKABIR DR, WYATT ME, VELLUCCI SV, HERBERT J: The effects of separate or combined infusions of corticotrophin-releasing factor and vasopressin either intraventricularly or into the amygdala on aggressive and investigative behaviour in the rat. Regul. Pept. (1990) 28:199-214.
121. PILLAR G, MALHOTRA A, LAVIE P: Post-traumatic stress disorder and sleep - what a nightmare! Sleep Med. Rev. (2000) 4:183-200.
122. McCURRY SM, GIBBONS LE, LOGSDON RG, TERI L: Anxiety and nighttime behavioral disturbances. Awakenings in patients with Alzheimer's disease. J. Gerontol. Nurs. (2004) 30:12-20.
123. SMOLLER JW, ROSENBAUM JF, BIEDERMAN J et al.: Association of a genetic marker at the corticotropin-releasing hormone locus with behavioral inhibition. Biol. Psychiatry (2003) 54:1376-1381.
124. ALBACH F, EVERAERD W: Posttraumatic stress symptoms in victims of childhood incest. Psychother. Psychosom. (1992) 57:143-151.
125. BRITTON DR, KOOB GF, RIVIER J, VALE W: Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty. Life Sci. (1982) 31:363-367.
126. DIAMANT M, CROISET G, DE WIED D: The effect of corticotropin-releasing factor (CRF) on autonomic and behavioral responses during shock-prod burying test in rats. Peptides (1992) 13:1149-1158.
127. PELTON GH, LEE Y, DAVIS M: Repeated stress, like vasopressin, sensitizes the excitatory effects of corticotropin releasing factor on the acoustic startle reflex. Brain Res. (1997) 778:381-387.
128. SWERDLOW NR, BRITTON KT, KOOB GF: Potentiation of acoustic startle by corticotropin-releasing factor (CRF) and by fear are both reversed by α-helical CRF (9-41). Neuropsychopharmacology (1989) 2:285-292.
129. DE JONGH R, GROENINK L, VAN DER GJ, OLIVIER B: Light-enhanced and fear-potentiated startle: temporal characteristics and effects of alpha-helical corticotropin-releasing hormone. Biol. Psychiatry. (2003) 54:1041-1048.
130. RASSNICK S, KOOB GF, GEYER MA: Responding to acoustic startle during chronic ethanol intoxication and withdrawal. Psychopharmacology (1992) 106:351-358.
131. SWERDLOW NR, GEYER MA, VALE WW, KOOB GF: Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. Psychopharmacology (1986) 88:147-152.
132. LIANG KC, MELIA KR, CAMPEAU S et al.: Lesions of the central nucleus of the amygdala, but not the paraventricular nucleus of the hypothalamus, block the excitatory effects of corticotropin-releasing factor on the acoustic startle reflex. J. Neurosci. (1992) 12:2313-2320.
133. LIANG KC, MELIA KR, MISERENDINO MJ et al.: Corticotropin-releasing factor: long-lasting facilitation of the acoustic startle reflex. J. Neurosci. (1992) 12:2303-2312.
134. RISBROUGH VB, HAUGER RL, PELLEYMOUNTER MA, GEYER MA: Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology (2003) 170:178-187.
135. GRILLON C, MORGAN CA, III, DAVIS M, SOUTHWICK SM: Effect of darkness on acoustic startle in Vietnam veterans with PTSD. Am. J. Psychiatry. (1998) 155:812-817.
136. GRILLON C, MORGAN CA 3rd, DAVIS M, SOUTHWICK SM: Effects of experimental context and explicit threat cues on acoustic startle in Vietnam veterans with posttraumatic stress disorder. Biol. Psychiatry. (1998) 44:1027-1036.
137. GRILLON C, DIERKER L, MERIKANGAS KR: Fear-potentiated startle in adolescent offspring of parents with anxiety disorders. Biol. Psychiatry (1998) 44:990-997.
138. FARADAY MM, O'DONOGHUE VA, GRUNBERG NE: Effects of nicotine and stress on startle amplitude and sensory gating depend on rat strain and sex. Pharmacol. Biochem. Behav. (1999) 62:273-284.
139. SIPOS ML, BAUMAN RA, WIDHOLM JJ, KANT GJ: Behavioral effects Of 8-OH-DPAT in chronically stressed mate and female rats. Pharmacol. Biochem. Behav. (2000) 66:403-411.
140. FARADAY MM: Rat sex and strain differences in responses to stress. Physiol. Behav. (2002) 75:507-522.
141. CONTI LH, MURRY JD, RUIZ MA, PRINTZ MP: Effects of corticotropin-releasing factor on prepulse inhibition of the acoustic startle response in two rat strains. Psychopharmacology (2002) 161:296-303.
142. BRAFF DL, GEYER MA, SWERDLOW NR: Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (2001) 156:234-258.
143. MIYAZATO H, SKINNER RD, GARCIA-RILL E: Locus coeruleus involvement in the effects of immobilization stress on the p13 midlatency auditory evoked potential in the rat. Prog. Neuropsychopharmacol. Biol. Psychiatry (2000) 24:1177-1201.
144. GRILLON C, MORGAN CA, SOUTHWICK SM, DAVIS M, CHARNEY DS: Baseline startle amplitude and prepulse inhibition in Vietnam veterans with posttraumatic stress disorder. Psychiatry Res. (1996) 64:169-178.
145. LUDEWIG S, LUDEWIG K, GEYER MA, HELL D, VOLLENWEIDER FX: Prepulse inhibition deficits in patients with panic disorder. Depress. Anxiety. (2002) 15:55-60.
146. SCHALL U, SCHON A, ZERBIN D, EGGERS C, OADES RD: Event-related potentials during an auditory discrimination with prepulse inhibition in patients with schizophrenia, obsessive-compulsive disorder and healthy subjects. Int. J. Neurosci. (1996) 84:15-33.
147. GHISOLFI ES, MARGIS R, BECKER J et al.: Impaired P50 sensory gating in post-traumatic stress disorder secondary to urban violence. Int. J. Psychophysiol. (2004) 51:209-214.
148. NEYLAN TC, FLETCHER DJ, LENOCI M et al.: Sensory gating in chronic posttraumatic stress disorder. reduced auditory P50 suppression in combat veterans. Biol. Psychiatry. (1999) 46:1656-1664.
149. SKINNER RD, RASCO LM, FITZGERALD J et al.: Reduced sensory gating of the P1 potential in rape victims and combat veterans with posttraumatic stress disorder. Depress. Anxiety (1999) 9:122-130.
150. GILLETTE GM, SKINNER RD, RASCO LM et al.: Combat veterans with posttraumatic stress disorder exhibit decreased habituation of the P1 midlatency auditory evoked potential. Life Sci. (1997) 61:1421-1434.
151. VELDHUIS HD, DE WIED D: Differential behavioral actions of corticotropin-releasing factor (CRF). Pharmacol. Biochem. Behav. (1984) 21:707-713.
152. TARJAN E, DENTON DA, WEISINGER RS: Corticotropin-releasing factor enhances sodium and water intake/excretion in rabbits. Brain Res. (1991) 542:219-224.
153. KALIN NH, SHELTON SE, BARKSDALE CM: Behavioral and physiologic effects of CRH administered to infant primates undergoing maternal separation. Neuropsychopharmacology (1989) 2:97-104.
154. STROME EM, WHELER GH, HIGLEY JD et al.: Intracerebroventricular corticotropin-releasing factor increases limbic glucose metabolism and has social context-dependent behavioral effects in nonhuman primates. Proc. Natl. Acad. Sci. USA (2002) 99:15749-15754.
155. BARRETT JE, ZRANG L, AHLERS ST, WOJNICKI FH: Acute and chronic effects of corticotropin-releasing factor on schedule-controlled responding and neurochemistry of pigeons. J. Pharmacol. Exp. Ther. (1989) 250:788-794.
156. ZHANG L, BARRETT JE: Interactions of corticotropin-releasing factor with antidepressant and anxiolytic drugs: behavioral studies with pigeons. Biol. Psychiatry. (1990) 27:953-967.
157. LEE Y, DAVIS M: Role of the hippocampus, the bed nucleus of the stria terminalis, and the amygdala in the excitatory effect of corticotropin-releasing hormone on the acoustic startle reflex. J. Neurosci. (1997) 17:6434-6446.
158. LIANG KC, LEE EH: Intra-amygdala injections of corticotropin releasing factor facilitate inhibitory avoidance learning and reduce exploratory behavior in rats. Psychopharmacology (1988) 96:232-236.
159. SAJDYK TJ, SCHOBER DA, GEHLERT DR, SHEKHAR A: Role of corticotropin-releasing factor and urocortin within the basolateral amygdala of rats in anxiety and panic responses. Behav. Brain Res. (1999) 100:207-215.
160. RADULOVIC J, RUHMANN A, LIEPOLD T, SPIESS J: Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J. Neurosci. (1999) 19:5016-5025.
161. KASK A, NGUYEN HP, PABST R, VON HORSTEN S: Neuropeptide Y Y1 receptor-mediated anxiolysis in the dorsocaudal lateral septum: functional antagonism of corticotropin-releasing hormone-induced anxiety. Neuroscience (2001) 104:799-806.
162. MARTINS AP, MARRAS RA, GUIMARAES FS: Anxiogenic effect of corticotropin-releasing hormone in the dorsal periaqueductal grey. Neuroreport (1997)8:3601-3604.
163. BUTLER PD, WEISS JM, STOUT JC, NEMEROFF CB: Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. J. Neurosci. (1990) 10:176-183.
164. DEAK T, NGUYEN KT, EHRLJCH AL et al.: The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology. (1999) 140:79-86.
165. ZORRILLA EP, SCHULTEIS G, ORMSBY A et al.: Urocortin shares the memory modulating effects of corticotropin-releasing factor (CRF): mediation by CRF1 receptors. Brain Res. (2002) 952:200-210.
166. STECKLER T, HOLSBOER F: Interaction between the cholinergic system and CRH in the modulation of spatial discrimination learning in mice. Brain Res. (2001) 906:46-59.
167. FISHER LA, BROWN MR: Corticotropin-releasing factor and angiotensin II: comparison of CNS actions to influence neuroendocrine and cardiovascular function. Brain Res. (1984) 296:41-47.
168. LENZ HJ, RAEDLER A, GRETEN H, BROWN MR: CRF initiates biological actions within the brain that are observed in response to stress. Am. J. Physiol. (1987) 252:R34-R39.
169. GROSSKREUTZ CL, BRODY MJ: Regional hemodynamic responses to central administration of corticotropin-releasing factor (CRF). Brain Res. (1988) 442:363-367.
170. OVERTON JM, FISHER LA: Central nervous system actions of corticotropin-releasing factor on cardiovascular function in the absence of locomotor activity. Regul. Pept. (1989) 25:315-324.
171. RICHTER RM, MULVANY MJ: Comparison of hCRF and oCRF efficts on cardiovascular responses after central, peripheral, and in vitro application. Peptides (1995) 16:843-849.
172. DIAMANT M, DE WIED D: Autonomic and behavioral effects of centrally administered corticotropin-releasing factor in rats. Endocrinology (1991) 129:446-454.
173. KORTE SM, EISINGA W, TIMMERMAN W, NYAKAS C, BOHUS B: Behavioral and cardiac responses after intracerebroventricular corticotropin-releasing hormone (CRH) administmtion: role of adrenal cortical hormones. Horm. Behav. (1992) 26:375-384.
174. DIAMANT M, KASHTANOV SI, FODOR M, DE WIED D: Corticotropin-releasing factor induces differential behavioral and cardiovascular effects after intracerebroventricular and lateral hypothalamic/perifornical injections in rats. Neuroendocrinology (1992) 56:750-760.
175. NIJSEN MJ, CROISET G, STAM R et al.: The role of the CRH Type 1 receptor in autonomic responses to corticotropin-releasing hormone in the rat. Neuropsychopharmacology (2000) 22:388-399.
176. IRWIN M, HAUGER R, BROWN M: Central corticotropin-releasing hormone activates the sympathetic nervous system and reduces immune function: increased responsivity of the aged rat. Endocrinology (1992) 131:1047-1053.
177. LINTHORST AC, FLACHSKAMM C, HOPKINS SJ et al.: Long-term
178. BUWALDA B, DE BOER SF, VAN KALKEREN AA, KOOLHAAS JM: Physiological and behavioral effects of chronic intracerebroventricular infusion of corticotropin-releasing factor in the rat. Psychoneuroendocrinology (1997) 22:297-309.
179. ROTHWELL NJ, HARDWICK A, LEFEUVRE RA, CROSBY SIZ, WHITE A: Central actions of CRF on thermogenesis are mediated by pro-opiomelanocortin products. Brain Res. (1991) 541:89-92.
180. DE FANTI BA, MARTINEZ JA: Central urocortin activation of sympathetic-regulated energy metabolism in Wistar rats. Brain Res. (2002) 930:3741.
181. GRILL HJ, MARKISON S, GINSBERG A, KAPLAN JM: Long-term effects on feeding and body weight after stimulation of forebrain or hindbrain CRH receptors with urocortin. Brain Res. (2000) 867.19-28.
182. BROWN MR, GRAY TS, FISHER LA: Corticotropin-releasing factor receptor antagonist: effects on the autonomic nervous system and cardiovascular function. Regul. Pept. (1986) 16:321-329.
183. SOLMAZ M, KAVUK I, SAYAR K: Psychological factors in the irritable bowel syndrome. Eur. J. Med. Res. (2003) 8:549-556.
184. HAZLETT-STEVENS H, CRASKE MG, MAYER EA, CHANG L, NALIBOFF BD: Prevalence of irritable bowel syndrome among university students: the roles of worry, neuroticism, anxiety sensitivity and visceral anxiety. J. Psychosom. Res. (2003) 55:501-505.
185. SYKES MA, BLANCHARD EB, LACKNER J, KEEFER L, KRASNER S: Psychopathology in irritable bowel syndrome: support for a psychophysiological model. J. Behav. Med. (2003) 26:361-372.
186. GARAKANI A, WIN T, VIRK S et al.: Comorbidity of irritable bowel syndrome in psychiatric patients: a review. Am. J. Ther. (2003) 10:61-67.
187. TACHÉ Y, MARTINEZ V, MILLION M, WANG L: Stress and the gastrointestinal tract III. Stress-related alterations of gut motor function: role of brain corticotropin-releasing factor receptors. Am. J. Physiol. Gastrointest. Liver Physiol. (2001) 280:G173-G177.
188. 2-mediated action on gastric transit in rats. Am. J. Physiol. Gastrointest. Liver Physiol. (2002) 282:G34-G40.
189. TACHÉ Y, MARTINEZ V, MILLION M, MAILLOT C: Role of corticotropin-releasing factor receptor subtype 1 in stress-related functional colonic alterations: implications in irritable bowel syndrome. Eur. J. Surg. (2002) 587(Suppl.): 168-170.
190. BREMNER JD, LICINIO J, DARNELL A et al.: Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am. J. Psychiatry. (1997) 154:624-629.
191. BAKER DG, WEST SA, NICHOLSON WE et al.: Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am. J. Psychiatry. (1999) 156:585-588.
192. SAUTTER FJ, BISSETTE G, WILEY J et al.: Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects. Biol. Psychiatry. (2003) 54:1382-1388.
193. KAYE WH, GWIRTSMAN HE, GEORGE DT et al.: Elevated cerebrospinal fluid levels of immunoreactive corticotropin-releasing hormone in anorexia nervosa: relation to state of nutrition, adrenal function, and intensity of depression. J Clin. Endocrinol. Metab. (1987) 64:203-208.
194. HOTTA M, SHIBASAKI T, MASUDA A et al.: The responses of plasma adrenocorticotropin and cortisol to corticotropin-releasing hormone (CRH) and cerebrospinal fluid immunoreactive CRH in anorexia nervosa patients. J. Clin. Endocrinol. Metab. (1986) 62:319-324.
195. ADINOFF B, ANTON R, LINNOILA M et al.: Cerebrospinal fluid concentrations of corticotropin-releasing hormone (CRH) and diazepam-binding inhibitor (DBI) during alcohol withdrawal and abstinence. Neuropsychopharmacology (1996) 15:288-295.
196. ARBORELIUS L, OWENS MJ, PLOTSKY PM, NEMEROFF CB: The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. (1999) 160:1-12.
197. NEMEROFF CB, OWENS MJ, BISSETTE G, ANDORN AC, STANLEY M: Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch. Gen. Psychiatry (1988) 45:577-579.
198. MERALI Z, DU L, HRDINA P et al.: Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J. Neurosci. (2004) 24:1478-1485.
199. ALTEMUS M, PIGOTT T, KALOGERAS KT et al.: Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder. Arch. Gen. Psychiatry (1992) 49:9-20.
200. FOSSEY MD, LYDIARD RB, BALLENGER JC et al.: Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects. Biol. Psychiatry (1996) 39:703-707.
201. ALTEMUS M, SWEDO SE, LEONARD HL et al.: Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Arch. Gen. Psychiatry (1994) 51:794-803.
202. CHAPPELL P, LECKMAN J, GOODMAN W et al.: Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: comparison to obsessive compulsive disorder and normal controls. Biol. Psychiatry (1996) 39:776-783.
203. SWEDO SE, LEONARD HL, KRUESI MJ et al.: Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. Arch. Gen. Psychiatry (1992) 49:29-36.
204. BANKI CM, KARMACSI L, BISSETTE G, NEMEROFF CB: Cerebrospinal fluid neuropeptides in mood disorder and dementia. J. Affect. Disord. (1992) 25:39-45.
205. JOLKKONEN J, LEPOLA U, BISSETTE G, NEMEROFF C, RIEKKINEN P: CSF corticotropin-releasing factor is not affected in panic disorder. Biol. Pychiatry (1993) 33:136-138.
206. BERRETTINI WH, NURNBERGER JI, JR., ZERBE RL et al.: CSF neuropeptides in euthymic bipolar patients and controls. Br. J. Psychiatry (1987) 150:208-212.
207. VIETA E, MARTINEZ-DE-OSABA MJ, COLOM F et al.: Enhanced corticotropin response to oorticotropin-releasing hormone as a predictor of mania in euthymic bipolar patients. Psychol. Med. (1999) 29:971-978.
208. RYBAKOWSKI JK, TWARDOWSKA K: The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness. J. Psychiatr. Res. (1999) 33:363-370.
209. SCHMIDER J, LAMMERS CH, GOTTHARDT U et al.: Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I. Biol. Psychiatry (1995) 38:797-802.
210. GILMOR ML, SKELTON KH, NEMEROFF CB, OWENS MJ: The effects of chronic treatment with the mood stabilizers valproic acid and lithium on corticotropin-releasing factor neuronal systems. J. Pharmacol. Exp. Ther. (2003) 305:434-439.
211. RIVIER J, RIVIER C, VALE W: Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. Science (1984) 224:889-891.
212. MENZAGHI F, HOWARD RL, HEINRICHS SC et al.: Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. J. Pharmacol. Exp. Ther. (1994) 269:564-572.
213. GULYAS J, RIVIER C, PERRIN M et al.: Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc. Natl. Acad. Sci. USA (1995) 92:10575-10579.
214. RIVIER J, GULYAS J, CORRIGAN A et al.: Astressin analogues (corticotropin-releasing factor antagonists) with extended duration of action in the rat. J. Med. Chem. (1998) 41:5012-5019.
215. SHIBASAKI T, YAMAUCHI N, HOTTA M et al.: Brain corticotropin-releasing hormone increases arousal in stress. Brain Res. (1991) 554:352-354.
216. SHIBASAKI T, IMAKI T, HOTTA M, LING N, DEMURA H: Psychological stress increases arousal through brain corticotropin-releasing hormone without significant increase in adrenocorticotropin and catecholamine secretion. Brain Res. (1993) 618:71-75.
217. SHIBASAKI T, IMAKI T, HOTTA M, LING N, DEMURA H: Restraint changes pentobarbital-induced sleeping time in rats: evidence that arousal is modulated by brain corticotropin-releasing hormone and opioid in stress. Regul. Pept. (1994) 51:141-149.
218. OJIMA Y, MATSUMOTO K, TOHDA M, WATANABE H: Hyperactivity of central noradrenergic and CRF systems is involved in social isolation-induced decrease in pentobarbital sleep. Brain Res. (1995) 694:87-94.
219. BERRIDGE CW, DUNN AJ: A corticotropin-releasing factor antagonist reverses the stress-induced changes of exploratory behavior in mice. Horm. Behav. (1987) 21:393-401.
220. MENZAGHI F, RASSNICK S, HEINRICHS S et al.: The role of corticotropin-releasing factor in the anxiogenic effects of ethanol withdrawal. Ann. NY Acad. Sci. (1994) 739:176-184.
221. HEINRICHS SC, MENZAGHI F, PICH EM et al.: Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity. Neuropsychopharmacology (1994) 11:179-186.
222. HEINRICHS SC, PICH EM, MICZEK KA, BRITTON KT, KOOB GF: Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res. (1992) 581:190-197.
223. RASSNICK S, HEINRICHS SC, BRITTON KT, KOOB GF: Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res. (1993) 605:25-32.
224. TAKAHASHI LK, KALIN NH, BAKER EW: Corticotropin-releasing factor antagonist attenuates defensive-withdrawal behavior elicited by odors of stressed conspecifics. Behav. Neurosci. (1990) 104:386-389.
225. TUCCI S, CHEETA S, SETH P, FILE SE: Corticotropin releasing factor antagonist, α-helical CRF(9-41), reverses nicotine-induced conditioned, but not unconditioned, anxiety. Psychopharmacology (2003) 167:251-256.
226. DEVRIES AC, PERT A: Conditioned increases in anxiogenic-like behavior following exposure to contextual stimuli associated with cocaine are mediated by corticotropin-releasing factor. Psychopharmacology (1998) 137:333-340.
227. VALDEZ GR, ZORRILLA EP, ROBERTS AJ, KOOB GF: Antagonism of corticotropin-releasing factor attenuates the enhanced responsiveness to stress observed during protracted ethanol abstinence. Alcohol (2003) 29:55-60.
228. SPINA MG, BASSO AM, ZORRILLA EP et al.: Behavioral effects of central administration of the novel CRF antagonist astressin in rats. Neuropsychopharmacology (2000) 22:230-239.
229. KALIN NH, SHERMAN JE, TAKAHASHI LK: Antagonism of endogenous CRH systems attenuates stress-induced freezing behavior in rats. Brain Res. (1988) 457:130-135.
230. KALIN NH, TAKAHASHI LK: Fear-motivated behavior induced by prior shock experience is mediated by corticotropin-releasing hormone systems. Brain Res. (1990) 509:80-84.
231. KORTE SM, KORTE-BOUWS GA, BOHUS B, KOOB GF: Effect of corticotropin-releasing factor antagonist on behavioral and neuroendocrine responses during exposure to defensive burying paradigm in rats. Physiol. Behav. (1994) 56:115-120.
232. BASSO AM, SPINA M, RIVIER J, VALE W, KOOB GF: Corticotropin-releasing factor antagonist attenuates the 'anxiogenic-like' effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats. Psychopharmacology (1999) 145:21-30.
233. JASNOW AM, RANKS MC, OWENS EC, HUHMAN KL: Differential effects of two corticotropin-releasing factor antagonists on conditioned defeat in male Syrian hamsters (Mesocricetus auratus). Brain Res. (1999) 846:122-128.
234. SWIERGIEL AH, TAKAHASHI LK, RUBIN WW, KALIN NH: Antagonism of corticotropin-releasing factor receptors in the locus coeruleus attenuates shock-induced freezing in rats. Brain Res. (1992) 587:263-268.
235. SWIERGIEL AH: Effects of infusion of corticotropin-releasing factor antagonist into the locus coeruleus on freezing behavior and brain catecholamines in rats. Acta Neurobiol. Exp. (2003) 63:9-16.
236. NIJSEN MJ, CROISET G, DIAMANT M, DE WIED D, WIEGANT VM: CRH signalling in the bed nucleus of the stria terminalis is involved in stress-induced cardiac vagal activation in conscious rats. Neuropsychopharmacology (2001) 24:1-10.
237. SWIERGIEL AH, TAKAHASHI LK, KALIN NH: Attenuation of stress-induced behavior by antagonism of corticotropin-releasing factor receptors in the central amygdala in the rat. Brain Res. (1993) 623:229-234.
238. NAKAMORI T, MORIMOTO A, MURAKAMI N: Effect of a central CRF antagonist on cardiovascular and thermoregulatory responses induced by stress or IL-1 beta. Am. J. Physiol. (1993) 265:R834-R839.
239. MORIMOTO A, NAKAMORI T, MORIMOTO K, TAN N, MURAKAMI N: The central role of corticotrophin-releasing factor (CRF-41) in psychological stress in rats. J. Physiol. (1993) 460:221-229.
240. NIJSEN MJ, CROISET G, DIAMANT M et al.: Endogenous corticotropin-releasing hormone inhibits conditioned-fear-induced vagal activation in the rat. Eur. J. Pharmacol. (2000) 389:89-98.
241. WILLIAMS CL, PETERSON JM, VILLAR RG, BURKS TF: Corticotropin-releasing factor directly mediates colonic responses to stress. Am. J. Physiol. (1987) 253:G582-G586.
242. GUE M, JUNIEN JL, BUENO L: Conditioned emotional response in rats enhances colonic motility through the central release of corticotropin-releasing factor. Gastroenterology (1991) 100:964-970.
243. MONNIKES H, SCHMIDT BG, TACHE Y: Psychological stress-induced accelerated colonic transit in rats involves hypothalamic corticotropin-releasing factor. Gastroenterology (1993) 104:716-723.
244. BONAZ B, TACHE Y: Water-avoidance stress-induced c-fos expression in the rat brain and stimulation of fecal output: role of corticotropin-releasing factor. Brain Res. (1994) 641:21-28.
245. MARTINEZ V, RIVIER J, WANG L, TACHE Y: Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric and colonic motor function. J. Pharmacol. Exp. Ther. (1997) 280:754-760.
246. MONNIKES H, SCHMIDT BG, RAYBOULD HE, TACHE Y: CRF in the paraventricular nucleus mediates gastric and colonic motor response to restraint stress. Am. J. Physiol. (1992) 262:G137-G143.
247. STENZEL-POORE MP, HEINRICHS SC, RIVEST S, KOOB GF, VALE WW: Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J. Neurosci. (1994) 14:2579-2584.
248. KASK A, RAGO L, HARRO J: α-helical CRF(9-41) prevents anxiogenic-like effect of NPYY1 receptor antagonist BIBP3226 in rats. Neuroreport (1997) 8:3645-3647.
249. BIRO E, SARNYAI Z, PENKE B, SZABO G, TELEGDY G: Role of endogenous corticotropin-releasing factor in mediation of neuroendocrine and behavioral responses to cholecystokinin octapeptide sulfate ester in rats. Neuroendocrinology (1993) 57:340-345.
250. GRIEBEL G, PERRAULT G, SANGER DJ: Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents: Comparison with diazepam and buspirone. Psychopharmacology (1998) 138:55-66.
251. BRITTON KT, LEE G, VALE W, RIVIER J, KOOB GF: Corticotropin releasing factor (CRF) receptor antagonist blocks activating and 'anxiogenic' actions of CRF in the rat. Brain Res. (1986) 369:303-306.
252. BRITTON KT, AKWA Y, SPINA MG, KOOB GF: Neuropeptide Y blocks anxiogenic-like behavioral action of corticotropin-releasing factor in an operant conflict test and elevated plus maze. Peptides (2000) 21:37-44.
253. IVERSEN SD: Animal models of anxiety and benzodiazepine actions. Arzneimittelforschung (1980) 30:862-868.
254. HEINRICHS SC, KLAASSEN A, KOOB GF et al.: Corticotropin-releasing factor receptor blockade enhances conditioned aversive properties of cocaine in rats. Psychopharmacology (1998) 136:247-255.
255. MILLAN MJ: The neurobiology and control of anxious states. Prog. Neurobiol. (2003) 70:83-244.
256. ETTENBERG A, GEIST TD: Animal model for investigating die anxiogenic effects of self-administered cocaine. Psychopharmacology (1991) 103:455-461.
257. DAVIS M, WALKER DL, MYERS KM: Role of the amygdala in fear extinction measured with potentiated starde. Ann. NY Acad. Sci. (2003) 985:218-232.
258. ROOZENDAAL B, BRUNSON KL, HOLLOWAY BL, McGAUGH JL, BARAM TZ: Involvement of stress-released corticotropin-releasing hormone in the basolateral amygdala in regulating memory consolidation. Proc. Natl. Acad. Sci. USA (2002) 99:13908-13913.
259. SAUVAGE M, STECKLER T: Detection of corticotropin-releasing hormone receptor 1 immunoreactivity in cholinergic, dopaminergic and noradrenergic neurons of the murine basal forebrain and brainstem nuclei-potential implication for arousal and attention. Neuroscience (2001) 104:643-652.
260. SARNYAI Z, HOHN J, SZABO G, PENKE B: Critical role of endogenous corticotropin-releasing factor (CRF) in the mediation of the behavioral action of cocaine in rats. Life Sci. (1992) 51:2019-2024.
261. CONTARINO A. DELLU F, KOOB GF et al.: Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Brain Res. (1999) 835:1-9.
262. TIMPL P, SPANAGEL R, SILLABER I et al.: Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat. Genet. (1998) 19:162-166.
263. MULLER MB, ZIMMERMANN S, SILLABER I et al.: Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat. Neurosci. (2003) 6:1100-1107.
264. LIEBSCH G, LANDGRAF R, ENGELMANN M, LORSCHER P, HOLSBOER F: Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain. J. Psychiatr. Res. (1999) 33:153-163.
265. LIEBSCH G, LANDGRAF R, GERSTBERGER R et al.: Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul. Pept. (1995) 59:229-239.
266. SKUTELLA T, PROBST JC, RENNER U, HOLSBOER F, BEHL C: Corticotropin-releasing hormone receptor (Type I) antisense targeting reduces anxiety. Neuroscience. (1998) 85:795-805.
267. HEINRICHS SC, LAPSANSKY J, LOVENBERG TW, DE SOUZA EB, CHALMERS DT: Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior. Regul. Pept. (1997) 71:15-21.
268. TAKAHASHI LK: Role of CRF(1) and CRF(2) receptors in fear and anxiety. Neurosci. Biobehav. Rev. (2001) 25:627-636.
269. OWENS MJ, NEMEROFF CB: Preclinical and clinical studies with corticotropin-releasing factor: implications for affective disorders. Psychopharmacol. Bull. (1988) 24:355-359.
270. HEINRICHS SC, TACHE Y: Therapeutic potential of CRF receptor antagonists: a gut-brain perspective. Expert Opin. Investig. Drugs (2001) 10:647-659.
271. CHRISTOS TE, ARVANITIS A: Corticotrophin-releasing factor receptor antagonists. Expert Opin. Ther. Patents (1998) 8:143-152.
272. AYALA AR, WAND GS: CRH receptor antagonists: advances and prospective. Expert Opin. Ther. Patents. (2000) 10:67-74.
273. LANIER M, WILLIAMS JP: Small molecule corticotropin-releasing factor antagonists. Expert Opin. Ther. Patents. (2002) 12:1619-1630.
274. HODGETTS KJ, YOON T, HUANG J et al.: 2-Aryl-3,6-dialkyl-5-dialkylaminopyrimidin-4-ones as novel CRF-1 receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13:2497-2500.
275. 1 receptor antagonist. I. Biochemical and pharmacological characterization. J. Pharmacol. Exp. Ther. (2002) 301:322-332.
276. WILSON DM, TERMIN AP, MAO L et al.: Arylamidrazones as novel corticotropin releasing factor receptor antagonists. J. Med. Chem. (2002) 45:2123-2126
277. LUTHIN DR, RABINOVICH AK, BHUMRALKAR DR et al.: Synthesis and biological activity of oxo-7H-benzo[e]perimidine-4-carboxylic acid derivatives as potent, nonpeptide corticotropin releasing factor (CRF) receptor antagonists. Bioorg. Med. Chem. Lett. (1999) 9:765-770.
278. NAKAZATO A, KUMAGAI T, OKUBO T et al.: Design, synthesis and structure-affinity relationships of 4-methylidenepiperidine and 4-aryl-1,2,3,6-tetrahydropyridine derivatives as corticotropin-releasing factor1 receptor antagonists. Bioorg. Med. Chem. (2000) 8:1183-1193.
279. McCLUSKEY A, KELLER PA, MORGAN J, GARNER J: Synthesis, molecular modeling and biological activity of methyl and thiomethyl substituted pyrimidines as corticotropin releasing hormone type 1 antagonists. Org. Biomol. Chem. (2003) 1:3353-3361.
280. DUBOWCHIK GM, MICHNE JA, ZUEV D et al.: 2-arylaminothiazoles as high-affinity corticotropin-releasing factor 1 receptor (CRF1R) antagonists: synthesis, binding studies and behavioral efficacy. Bioorg. Med. Chem. Lett. (2003) 13:3997-4000.
281. HOARE SR, SULLIVAN SK, LING N, CROWE PD, GRIGORIADIS DE: Mechanism of corticotropin-releasing factor Type I receptor regulation by nonpeptide antagonists. Mol. Pharmacol. (2003) 63:751-765.
282. LIAW CW, GRIGORIADIS DE, LORANG MT, DE SOUZA EB, MAKI RA: Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol. Endocrinol. (1997) 11:2048-2053.
283. GILLIGAN PJ, BALDAUF C, COCUZZA A et al.: The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl -pyrazolo-[1,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist. Bioorg. Med. Chem. (2000) 8:181-189.
284. MONASSIER L, BOUSQUET P: Sigma receptors: from discovery to highlights of their implications in the cardiovascular system. Fundam. Clin. Pharmacol. (2002) 16:1-8.
285. WAN CP, LAU BH: Neuropeptide Y receptor subtypes. Life Sci. (1995) 56:1055-1064.
286. HSIN LW, TIAN X, WEBSTER EL et al.: CRHR1 receptor binding and lipophilicity of pyrrolopyrimidines, potential nonpeptide oorticotropin-releasing hormone Type 1 receptor antagonists. Bioorg. Med. Chem. (2002) 10:175-183.
287. CHORVAT RJ, BAKTHAVATCHALAM R, BECK JP et al.: Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines. J. Med. Chem. (1999) 42:833-848.
288. ARVANITIS AG, RESCINITO JT, ARNOLD CR et al.: Imidazo[4,5-c]pyridines as corticotropin releasing factor receptor ligands. Bioorg. Med. Chem. Lett. (2003) 13:129-131.
289. ARVANITIS AG, RESCINITO JT, ARNOLD CR et al.: Imidazo[4,5-b]pyridines as corticotropin releasing factor receptor ligands. Bioorg. Med. Chem. Lett. (2003) 13:125-128.
290. WILCOXEN K, HUANG CQ, McCARTHY JR, GRIGORIADIS DE, CHEN C: Synthesis of 3-phenylpyrazolo[4,3-b]pyridines via a convenient synthesis of 4-amino-3-arylpyrazoles and SAR of corticotropin-releasing factor receptor type-1 antagonists. Bioorg. Med. Chem. Lett. (2003) 13:3367-3370.
291. HUANG CQ, WILCOXEN K, McCARTHY JR et al.: Synthesis and SAR of 8-arylquinolines as potent corticortopin-releasing factor1 (CRF1) receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13:3375-3379.
292. HUANG CQ, WILCOXEN K, McCARTHY JR et al.: Synthesis of 1-methyl-3-phenylpyrazolo[4,3-b]pyridines via a methylation of 4-phthalimino-3-phenylpyrazoles and optimization toward highly potent corticotropin-releasing factor type-1 antagonists. Bioorg. Med. Chem. Lett. (2003) 13:3371-3374.
293. HEINRICHS SC, DE SOUZA EB, SCHULTEIS G, LAPSANSKY JL, GRIGORIADIS DE: Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor Type I receptor selective antagonist. Neuropsychopharmacology (2002) 27:194-202.
294. HE L, GILLIGAN PJ, ZACZEK R et al.: 4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist. J. Med. Chem. (2000) 43:449-456.
295. HABIB KE, WELD KP, RICE KC et al.: Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc. Natl. Acad. Sci. USA (2000) 97:6079-6084.
296. KELLER C, BRUELISAUER A, LEMAIRE M, ENZ A: Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist. Drug Metab. Dispos. (2002) 30:173-176.
297. LI YW, HILL G, WONG H et al.: Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy. J. Pharmacol. Exp. Ther. (2003) 305:86-96.
298. HANSCH C, BJORKROTH JP, LEO A: Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. J. Pharm. Sci. (1987) 76:663-687.
299. LIPINSKI CA, LOMBARDO F, DOMINY BW, FEENEY PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. (2001) 46:3-26.
300. OPREA TI, DAVIS AM, TEAGUE SJ, LEESON PD: Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. (2001) 41:1308-1315.
301. TEAGUE SJ, DAVIS AM, LEESON PD, OPREA T: The design of leadlike combinatorial libraries. Angew. Chem. Int. Ed. Engl. (1999) 38:3743-3748.
302. BANG LM, CHAPMAN TM, GOA KL: Lercanidipine: a review of its efficacy in the management of hypertension. Drugs. (2003) 63:2449-2472.
303. LIN JH, LU AY: Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. (1997) 49:403-449.
304. WENINGER SC, DUNN AJ, MUGLIA LJ et al.: Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH. Proc. Natl. Acad. Sci. USA (1999) 96:8283-8288.
305. 1 antagonist DMP904 administered acutely or chronically at doses occupying central CRF1 receptors in rats. J. Pharmacol. Exp. Ther. (2004) 309:293-302.
306. HOTTA M, SHIBASAKI T, ARAI Y, DEMURA H: Corticotropin-releasing factor receptor Type 1 mediates emotional stress-induced inhibition of food intake and behavioral changes in rats. Brain Res. (1999) 823:221-225.
307. ZORRILLA E, FEKETE E, MASON BJ et al.: CRF1 antagonists for anxiety. Eur. Neuropsychopharmacol. (2003) 13:130.
308. GRIEBEL G, SIMIAND J, STEINBERG R et al.: 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro -4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J. Pharmacol. Exp. Ther. (2002) 301:333-345.
309. ARAI K, OHATA H, SHIBASAKI T: Non-peptidic corticotropin-releasing hormone receptor Type 1 antagonist reverses restraint stress-induced shortening of sodium pentobarbital-induced sleeping time of rats: evidence that an increase in arousal induced by stress is mediated through CRH receptor type 1. Nearosci. Lett. (1998) 255:103-106.
310. LANCEL M, MULLER-PREUSS P, WIGGER A, LANDGRAF R, HOLSBOER F: The CRH1 receptor antagonist R121919 attenuates stress-elicited sleep disturbances in rats, particularly in those with high innate anxiety. J. Psychiatr. Res. (2002) 36:197-208.
311. LELAS S, ZELLER KL, WARD KA, MCELROY JF: The anxiolytic CRF(1) antagonist DMP696 fails to function as a discriminative stimulus and does not substitute for chlordiazepoxide in rats. Psychopharmacology (2003) 166:408-415.
312. ARBORELIUS L, SKELTON KH, THRIVIKRAMAN KV et al.: Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat. J. Pharmacol. Exp. Ther. (2000) 294:588-597.
313. OHATA H, ARAI K, SHIBASAKI T: Effect of chronic administration of a CRF(1) receptor antagonist, CRA1000, on locomotor activity and endocrine responses to stress. Eur. J. Pharmacol. (2002) 457:201-206.
314. GUTMAN DA, OWENS MJ, SKELTON KH, THRIVIKRAMAN KV, NEMEROFF CB: The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress. J. Pharmacol. Exp. Ther. (2003) 304:874-880.
315. JAMES SE, GHOSH SJ, MONTGOMERIE J, PHILP BM, DZIEWULSKI P: Survival of a 75% burn in a patient with longstanding Addison's disease. Burns (2002) 28:391-393.
316. SIBBALD WJ, SHORT A, COHEN MP, WILSON RF: Variations in adrenocortical responsiveness during severe bacterial infections. Unrecognized adrenocortical insufficiency in severe bacterial infections. Ann. Surg. (1977) 186:29-33.
317. LU L, LIU Z, HUANG M, ZHANG Z: Dopamine-dependent responses to cocaine depend on corticotropin-releasing factor receptor subtypes. J. Neurochem. (2003) 84:1378-1386.
318. 1 antagonist block the acquisition of opiate withdrawal-induce conditioned place aversion in rats. Neuropsychopharmacology (In press).
319. BROADBEAR JH, WINGER G, RICE KC, WOODS JH: Antalarmin, a putative CRH-RI antagonist, has transient reinforcing effects in rhesus monkeys. Psychopharmacology (2002) 164:268-276.
320. BROADBEAR JH, WINGER G, RIVIER JE, RICE KC, WOODS JH: Corticotropin-releasing hormone antagonists, astressin B and antalarmin: differing profiles of activity in rhesus monkeys. Neuropsychopharmacology (2004) 29(6):1112-21
321. ZOBEL AW, NICKEL T, KUNZEL HE et al.: Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. (2000) 34:171-181.
322. HELD K, KUNZEL H, ISING M et al.: Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression J. Psychiatr. Res. (2004) 38:129-136.
323. KUNZEL HE, ZOBEL AW, NICKEL T et al.: Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. J. Psychiatr. Res. (2003) 37:525-533.
324. MARTARELLO L, KILTS CD, ELY T et al.: Synthesis and characterization of fluorinated and iodinated pyrrolopyrimidines as PET/SPECT ligands for the CRF1 receptor. Nucl. Med. Biol. (2001) 28:187-195.
325. 3H]SN003) for corticotropin-releasing factor1 receptors. J. Pharmacol. Exp. Ther. (2003) 305:57-69.
326. JAGODA E, CONTOREGGI C, LEE MJ et al.: Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: synthesis of [(76)Br]MJL-1-109-2. J. Med. Chem. (2003) 46:3559-3562.
327. CHAKI S, NAKAZATO A, KENNIS L et al.: Anxiolytic- and antidepressant-like profile of a new CRF(1) receptor antagonist, R278995/CRA0450. Eur. J. Pharmacol. (2004) 485:145-158.
328. BURT DR, CREESE I, SNYDER SH: Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science (1977) 196:326-328.
329. LAVREYSEN H, LE POUL E, VAN GOMPEL P et al.: Supersensitivity of human metabotropic glutamate 1a receptor signaling in L929sA cells. Mol. Pharmacol. (2002) 61:1244-1254.
330. YUAN J, GULIANELLO M, DE LOMBAERT S et al.: 3-Aryl pyrazolo[4,3-d]pyrimidine derivatives: Nonpeptide CRF-1 antagonists. Bioorg. Med. Chem. Lett. (2002) 12:2133-2136.
331. GILLIGAN PJ, FOLMER BK, HART RA et al.: Pyrazolo-[1,5-a]-1,3,5-triazine corticotropin-releasing factor (CRF) receptor ligands. Bioorg. Med. Chem. (2003) 11:4093-4102.
332. SEYMOUR PA, SCHMIDT AW, SCHULZ DW: The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: A review. CNS Drug Rev. (2003) 9:57-96.
333. GILLIGAN PJ, ROBERTSON DW, ZACZEK R: Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. J. Med. Chem. (2000) 43:1641-1660.
334. McCARTHY JR, HEINRICHS SC, GRIGORIADIS DE: Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Curr. Pharm. Des. (1999) 5:289-315.
335. MILLION M, GRIGORIADIS DE, SULLIVAN S et al.: A novel water-soluble selective CRF1 receptor antagonist, NBI 35965, blunts stress-induced visceral hyperalgesia and colonic motor function in rats. Brain Res. (2003) 985:3242.
336. ROSSANT CJ, PINNOCK RD, HUGHES J, HALL MD, McNULTY S: Corticotropin-releasing factor type 1 and type 2α receptors regulate phosphorylation of calcium/cyclic adenosine 3′,5′ -monophosphate response element-binding protein and activation of p42/p44 mitogen-activated protein kinase. Endocrinology (1999) 140:1525-1536.
337. MACKAY KB, BOZIGIAN H, GRIGORIADIS DE et al.: Neuroprotective effects of the CRF1 antagonist R121920 after permanent focal ischemia in the rat. J. Cereb. Blood Flow Metab. (2001) 21:1208-1214.
338. GILLIGAN PJ, HARTIG PR, ROBERTSON DW, ZACZEK R: Corticotrophin-releasing hormone (CRH) receptors and the discovery of selective non-peptide CRH antagonism. Ann. Rep. Med. Chem. (1997) 32:41-50.
339. MILLAN MJ, BROCCO M, GOBERT A et al.: Anxiolytic properties of the selective, non-peptidergic corticotropin-releasing factor (CRF)1 antagonists, CP154,526 and DMP 695: a comparison to other classes of
340. KECK M, WELT T, WIGGER A et al.: The anxiolytic effect of the CRH1 receptor antagonist R121919 depends on innate emotionality in rats. Eur. J. Neurosci. (2001) 13:373-380.
341. McELROY JF, WARD KA, ZELLER KL et al.: The CRF(1) receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats. Psychopharmacology (2002) 165:86-92.
342. HARRO J, TONISSAAR M, ELLER M: The effects of CRA 1000, a non-peptide antagonist of corticotropin-releasing factor receptor Type 1, on adaptive behaviour in the rat. Neuropeptides (2001) 35:100-109.
343. MACIAG CM, DENT G, GILLIGAN P et al.: Effects of a non-peptide CRF antagonist (DMP696) on the behavioral and endocrine sequelae of maternal separation. Neuropsychopharmacology (2002) 26:574-582.
344. OVERSTREET DH, KNAPP DJ, BREESE GR: Modulation of multiple ethanol withdrawal-induced anxiety-like behavior by CRF and CRF(1) receptors. Pharmacol. Biochem. Behav. (2004) 77:405-413.
345. KEHNE JH, COVERDALE S, McCLOSKEY TC, HOFFMAN DC, CASSELLA JV: Effects of the CRF(1) receptor antagonist, CP 154,526, in the separation-induced vocalization anxiolytic test in rat pups. Neuropharmacol. (2000) 39:1357-1367.
346. KIKUSUI T, TAKEUCHI Y, MORI Y: Involvement of corticotropin-releasing factor in the retrieval process of fear-conditioned ultrasonic vocalization in rats. Physiol. Behav. (2000) 71:323-328.
347. HIKICHI T, AKIYOSHI J, YAMAMOTO Y et al.: Suppression of conditioned fear by administration of CRF receptor antagonist CP-154,526. Pharmacopsychiatry (2000) 33:189-193.
348. HO SP, TAKAHASHI LK, LIVANOV V et al.: Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing fictor-2 receptor. Brain Res. Mol. Brain Res.. (2001) 89:29-40.
349. CHEN YL, MANSBACH RS, WINTER SM et al.: Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing fiactor1 receptor antagonist. J. Med. Chem. (1997) 40:1749-1754.
350. LUNDKVIST J, CHAI Z, TEHERANIAN R et al.: A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur. J. Pharmacol. (1996) 309:195-200.
351. HOPE PJ, TURNBULL H, FARR S et al.: Peripheral administration of CRF and urocortin: effects on food intake and the HPA axis in the marsupial Sminthopsis crassicaudata. Peptides (2000) 21:669-677.
352. BORNSTEIN SR, WEBSTER EL, TORPY DJ et al.: Chronic effects of a nonpeptide corticotropin-releasing hormone Type I receptor antagonist on pituitary-adrenal function, body weight, and metabolic regulation. Endocrinology (1998) 139:1546-1555.
353. WONG ML, WEBSTER EL, SPOKES H et al.: Chronic administration of the nonpeptide CRH Type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress. Life Sci. (1999) 65:PL53-PL58.